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Abstract
Metaiodobenzylguanidine (MIBG), a noradrenaline analogue, 
labelled with radioactive iodine I-123 is used for assessing 
pre-synaptic activity of the myocardial adrenergic system. The 
paper describes the mechanism of myocardial I-123-MIBG up-
take and the relevant examination methods. It also refers to the 
necessity of standardising acquisition methods and assessment 
criteria in order to improve comparability of results, especially 
numerical results, originating from various countries and centres. 
Although first introduced as a cardiological diagnostic procedure 
30 years ago, I-123-MIBG myocardial scintigraphy continues to 
be mostly applied as a research method, even though its dia-
gnostic and/or prognostic importance, especially in the case of 
heart failure, has been widely reported. The recently published 
results of two extensive retrospective works and a major pro-
spective, multi-centre international ADMIRE-HF study confirmed 
that I-123-MIBG scintigraphy has a high independent prog-
nostic value in evaluating patients with heart failure. Abnormal 
myocardial I-123-MIBG uptake can also be indicative of higher 
risk of ventricular arrhythmias and sudden cardiac death in 
patients with heart failure. I-123-MIBG myocardial scintigraphy 
also seems to have considerable potential for the detection and 
differentiation of neurodegenerative diseases.
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Introduction
The autonomic nervous system consists of the adrenergic 
(sympathetic) system with stimulating action — and noradrenaline 
as the main transmitter, and the cholinergic (parasympathetic) 
system with inhibiting action — and acetylcholine as the main 
transmitter. The imaging of the cardiac cholinergic system is very 
limited due to the low density of parasympathetic nerves in the 
ventricular muscles and the lack of appropriate analogues of 
acetylcholine, which undergoes rapid decomposition in the pre-
synaptic nerve terminals, suitable for radioisotope examinations. 
However, the adrenergic fibres are abundant in the heart — they 
run in the epicardium along the coronary arteries and penetrate 
the myocardium similarly as the smaller coronary vessels; they are 
present in the ventricles (in particular at the base thereof) and to 
a significant extent are more concentrated in the atria.
Metaiodobenzylguanidine (MIBG) is a chemical analogue 
of noradrenaline — its uptake and storage mechanisms in the 
adrenergic nerve terminals are similar to those of noradrenaline, 
while it hardly undergoes metabolism and remains unchanged for 
a longer period of time in the nerve terminals — therefore, when 
labelled with radioactive iodine, it is considered a pharmaceuti-
cal suitable for the assessment of the presynaptic portion of the 
cardiac adrenergic innervation [1–6]. 
As the radiation energy (159 keV) of radioactive iodine I-123 
is comparable to that of technetium Tc-99m (thus it is possible to 
use low-energy collimators and acquire relatively high-resolution 
scintigraphic images) and it has comparatively short half-life 
(13.3 h), it currently seems to be the best one of the available 
iodine radioisotopes for MIBG labelling.
The I-123-MIBG radiotracer, used for assessing the presynaptic 
part of the adrenergic system, is the most extensively researched 
and practically the only radiotracer available in the classical scin-
tigraphy of the cardiac autonomic nervous system. This radiotracer 
was first used for the assessment of a human heart by Kline et 
al. in 1981 [1].
Other imaging agents include noradrenaline analogues labelled 
with positron radiotracers for PET scintigraphy (hydro xyephedrine, 
epinephrine and phenylephrine labelled with C-11 [7] and a com-
pletely new LMI1195 radiotracer for labelling with F-18 which 
has a longer half-life [8]). 
The research is also underway into the labelling of post-synap-
tic receptors which transmit signals from the adrenergic system to 
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the myocardial tissue, regulating the chronotropic, inotropic and 
dromotropic effects within the myocardium. There are reports of 
clinical applications of the CGP12177 positron radiotracer la-
belled with C-11 – non-selective hydrophilic compound binding 
to beta-receptors – to demonstrate their myocardial density in 
diagnosing [9] and prognosing [10] based on PET scintigraphy.
Description of MIBG uptake,  
examination methods  
and interpretation of results
Mechanism of the myocardial MIBG uptake
Following intravenous administration, MIBG diffuses from the 
vascular to the intracellular space, and from there it is actively 
transported, similarly as noradrenaline, to the adrenergic termi-
nals or a small fraction of MIBG diffuses (to neurons, muscle cells, 
the vascular space).
The first mechanism (so-called uptake-1, energy-dependent) 
is the prevailing mechanism. From the synaptic cleft, MIBG un-
dergoes active uptake at the nerve terminal which is facilitated by 
the specific noradrenaline monoamine transporter (NET) protein 
and most of the radiotracer, by means of another active transport 
process facilitated by the specific vesicular monoamine transporter 
(VMAT) protein, is stored in noradrenaline-storing vesicles in the 
neuron’s terminal. Uptake-1 becomes saturated. Nerve stimulation 
induces the secretion of noradrenaline and MIBG: vesicles combine 
with the neuron’s membrane and secrete their content to the synap-
tic space by exocytosis. Metaiodobenzylguanidine is re-transported 
to the nerve terminal by the uptake-1 mechanism or diffuses (into the 
vascular space and conceivably to neurons, and also to myocytes in 
animals). Unlike the noradrenaline fraction which is not stored in the 
vesicles, but metabolised in the cytosol of the nerve terminal [by 
monoamine oxidase (MAO)], MIBG is not catabolised — therefore 
the extravesicular concentration of MIBG is larger than that of no-
radrenaline. Metaiodobenzylguanidine can diffuse from the cytosol 
of the nerve terminal into the intracellular space. 
The mechanism eliminating noradrenaline into the extraneural 
tissue (sometimes called uptake-2) is probably based on passive 
diffusion. Uptake-2 has no saturation point. It was shown using 
animal models that the extraneural uptake-2 of MIBG can reach 
a significant level. However, it is not the same in humans — no 
MIBG uptake is observed in the transplanted (and initially fully 
de-innervated) heart until at least 4 months after the transplanta-
tion. In contrast to noradrenaline, MIBG in the cardiomyocyte cy-
tosol is not catabolised by catechol-O-methyltransferase (COMT).
The compound exhibits low affinity to post-synaptic adrenergic 
receptors, and for that reason — as opposed to noradrenaline 
— has a highly insignificant pharmacological effect.
It was demonstrated that the level of myocardial MIBG uptake 
is correlated with the myocardial noradrenaline level [13] and it 
is explicitly dependent on the presence of non-damaged sympa-
thetic nerve fibres [14–17].
MIBG pharmacokinetics and pharmacodynamics
The dynamics of myocardial MIBG accumulation can be 
described as follows:
 — after intravenous administration, myocardial MIBG uptake 
follows immediately and achieves a stable level after 2–3 mi-
nutes [60], after 60 minutes it reaches about 1% of the ad-
ministered dosage [1]; 
 — intravesicular myocardial accumulation of I-123-MIBG is rela-
tively constant starting from the 5th minute after administration, 
while extravesicular myocardial accumulation decreases to 
a significant extent between the 5th minute and 6th hour after 
the administration; the intravesicular percentage of the total 
myocardial accumulation achieves a constant (and maximal) 
value equal to 50% within 4 hours after the administration; 
hence it is considered that images acquired about 4 hours after 
the injection of the tracer would best reflect the neuronal MIBG 
uptake in the heart [19].
MIBG pharmacokinetics and pharmacodynamics in the human 
body is as follows:
 — I-123-MIBG blood level decreases quite rapidly: about 10% 
of the injected dosage remains in blood after 5 minutes from 
the administration, about 5% after 15 minutes, and about 2% 
after 1 hour [1];
 — the highest MIBG fraction is accumulated in the liver (about 
0.33 of the administered dosage), the greatest uptake is ob-
served in the lungs (about 0.03), the heart (0.008), the spleen 
(about 0.006) and in the salivary glands (about 0.004);
 — tracer uptake in the liver is always greater compared to the 
heart: the ratio of the myocardial-to-hepatic uptake is about 
0.7 after 15 minutes and remains at 0.3–0.6 during the next 
24 hours [1, 11, 20];
 — tracer uptake in the lungs is always smaller compared to the 
myocardium: the ratio of the myocardial-to-pulmonary uptake 
is about 1.2 after 15 minutes, 1.4 after 2 hours and 2.9 after 
24 hours [1, 11];
 — I-123-MIBG is excreted from the body through the kid-
neys — 85–90% as an unchanged compound (scarcely 
any amount of the tracer is metabolised in living orga nisms) 
and about 10% as a de-iodinated compound; 55% of MIBG 
is excreted within 24 hours after the injection and 90% after 
4 days.
Impact of medication on MIBG accumulation  
and preparation of patients for examination
A number of drugs are known or can be assumed to have 
an impact on the MIBG uptake and/or storage [21–23, 24]. 
Patients should be taken off such medication (if possible) for 
a sufficiently long period of time before the examination. If it is im-
possible to discontinue medication, at least its possible impact on 
the acquired images of the adrenergic system should be taken 
into consideration. 
There are several mechanisms which affect — separately 
or jointly after the administration of specific drugs — the MIBG 
storage process (approved names of the drugs which have been 
demonstrated to influence the MIBG uptake in specific organs are 
given in brackets):
 — inhibited active uptake (cocaine, tricyclic antidepressants, 
labetalol);
 — inhibited active transport to vesicles (reserpine);
 — competition for vesicular transport (guanethidine);
 — secretion of the vesicular content (sympathomimetic drugs, 
labetalol, reserpine);
 — other non-explained mechanisms. 
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It is also recommended that patients should refrain from 
consuming foods containing vanilla and catecholamine-like in-
gredients (e.g. chocolate, blue cheese) as some of them might 
interfere with the MIBG uptake. 
MIBG is usually administered after the uptake of free io-
dine-123 by the thyroid is blocked. The thyroid can be blocked by 
administering potassium or sodium perchlorate (400–500 mg) or 
Lugol’s iodine (equivalent of 130 mg of potassium iodide) at least 
30 minutes before the MIBG injection [24, 25]. 
Patients should drink plenty of liquids and frequently urinate for 
the first 48 hours after the administration of MIBG to accelerate the 
excretion of the radiopharmaceutical from their bodies and reduce 
the exposure of the bladder and the whole body to radiation.
MIBG examinations of the myocardial  
adrenergic system
Acquisition parameters recommended for cardiac I-123-MIBG 
studies are shown in Table 1.
Normal-weight adult patients are administered a dosage of 
111-370 MBq (3–10 mCi) of the radiopharmaceutical [25].
The effective dosage received by an adult patient after the 
administration of I-123-MIBG is 0.013 mSv/MBq (i.e. a standard 
patient administered 370 MBq of the radiopharmaceutical re-
ceives a dosage of 4.81 mSv).
MIBG should be administered intravenously very slowly (for at 
least 1–2 minutes according to [25], and for at least 5 minutes ac-
cording to [24]).
During the acquisition of scintigraphic images a 15- or 20-per-
cent energy window is used, positioned symmetrically around the 
iodine-123 photopeak (159 keV).
Planar images of the chest are registered (anterior projection, 
128 ¥ 128 matrix, acquisition time — 10 minutes); early images are 
registered 15 minutes, and late images 4 hours after the admi-
nistration of the radiopharmaceutical. As the planar technique 
is known to have limitations (overlapping images of extra-cardiac 
structures and myocardium as well as no possibility of segmen-
tal analysis), additional SPECT images (64 ¥ 64 matrix) can be 
registered immediately after the registration of planar images. 
Medium-energy collimators are preferred in the case of 
iodine-123 as in addition to the primary emission of photons at 
159 keV, iodine-123 emits also about 3% of photons at > 400 
keV which leads to the penetration of the septa in low-energy 
high-resolution (LEHR) collimators and causes a high contribu-
tion of scattered radiation to the energy window around 159 keV. 
Medium-energy collimators enable better diagnostic accuracy of 
I-123 examinations compared to low-energy collimators. However, 
so far nearly every report relating to the quantitative assessment 
of the myocardial I-123-MIBG uptake in patients with heart failure 
(including all 96 centres registered in the most extensive prospec-
tive international study — ADMIRE-HF [26], 5/6 centres included in 
the retrospective multi-centre European study [27] and probably 
17/18 works underlying a meta-analysis of the best studies [28]) 
was based on the acquisition of images with low-energy collima-
tors. The numerical data gathered in these studies cannot be used 
for interpreting results obtained with medium-energy collimators.
Assessment of the global myocardial MIBG uptake 
based on the planar examination
The methods underlying the assessment of MIBG myocardial 
planar examinations are based on a semi-quantitative measure-
ment of the global radiotracer uptake in the heart after 15 mi-
nutes and/or 4 hours from its administration and/or the washout 
rate of the tracer from the heart between the 15th minute and 4th 
hour from its administration.
The global uptake of I-123-MIBG is most often expressed as the 
H/M ratio, i.e. the ratio of the average number of counts within the 
heart to the average number of counts within the mediastinum 
(i.e. the background) after the examined area of the heart and 
the upper part of the sternum are mapped onto the scintigraphic 
planar image in anterior projection [25] (Figure 1). The H/M ratio 
after 15 minutes (H/M15m) most probably reflects the continuity 
of pre-synaptic nerve terminals and the functioning of uptake-1. 
The H/M ratio after 4 hours (H/M4h) enables integrating informa-
tion about the neuronal function, starting from the MIBG uptake, 
through storage, up to the ejection from the storing vesicles in 
the nerve terminals. It was demonstrated that the H/M ratio after 
Table 1. Recommended acquisition parameters for cardiac I-123-MIBG studies [25] 
Parameter Value/Description
Energy window: 20% symmetrically around 159 keV
Collimators: Low energy high resolution (LEHR) or medium energy (ME)
Planar imaging:
— projection: Anterior
— matrix: 128 ¥ 128 or 256 ¥ 256
— starting time p.i.: 10 min and 4 h
— length of each acquisition: 10 min
SPECT imaging:
— detectors: Single or dual heads (in a 90° or “L” configuration)
— rotation: 180° (starting at 45° right anterior oblique projection and proceeding anticlockwise to the 45° left 
posterior oblique projection)
— number of projections: 64
— time/projection: 20/25 s
— overall acquisition time: ≤ 25 min
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4 hours is correlated with the total myocardial MIBG uptake re-
ferred to as % of the uptake of the administered dosage (r = 0.72, 
p < 0.0001) [29]. Furthermore the H/M ratio is correlated with the 
myocardial noradrenaline level (r = 0.63) [13]. Thus, the H/M ratio 
is a measure of the global myocardial MIBG uptake and can be 
used as a practical rate of uptake [29–31].
The washout rate (WR) of MIBG from the heart is most often 
expressed as a percentage difference between the average num-
ber of counts within the heart after 15 minutes and 4 hours and 
the average number of counts within the heart after 15 minutes. 
However, there is a wide variety of calculation methods — with or 
without standardisation of H-to-M counts, with or without back-
ground correction by subtracting M counts from H counts, with 
or without correction for radioisotope decay in time [25, 32, 33]. 
The washout rate of MIBG from the heart indicates the excitation 
level of the adrenergic system (greater activity of the myocardial 
adrenergic system is related to the high WR value and low MIBG 
uptake in late images). Nonetheless, there are doubts about 
the interpretation of the washout rate — most probably it re-
presents several mechanisms (at least vesicular exocytosis and 
extravesicular diffusion in the nerve terminals). Greater WR va-
lues were described in a number of cardiological diseases — but 
the mechanisms responsible for the phenomenon have not been 
fully explained.
Most often the H/M ratio, in particular after 4 hours from the 
MIBG administration, is considered to be the most important 
factor in the global assessment of the myocardial adrenergic 
system — also on account of the larger number of studies in 
which this parameter was tested. However, it has not been un-
ambiguously determined whether any single parameter — H/M 
or WR — or their combination should be taken into consideration 
in the prognostic process. 
SPECT-based assessment of the regional 
myocardial MIBG uptake
The papers known from the literature on the SPECT-based 
examination of “normal” myocardial I-123-MIBG uptake, performed 
within several hours after the administration of radiotracer, were 
related to the relative assessment of the radiotracer distribution in 
specific regions of the left-ventricular muscle and the determination 
of the correlation between the distribution and the patient’s sex 
and/or age [34–38]. Normal I-123-MIBG uptake in the left-ven-
tricular muscle is non-uniform and depends on the patient’s age 
and probably sex. It also seems that the normal relative uptake in 
specific regions is comparable to the relative uptake of perfusion 
tracers in the muscle: the greatest number of counts is observed 
above the anterolateral wall, the lowest number above the lower 
wall (especially in men). Reduced number of counts can be present 
in the apex. The nerves of the cardiac adrenergic system are more 
sensitive to ischaemia than cardiomyocytes. Therefore, the de-
fects observed in MIBG rest images are bigger (more extensive and 
more intense) than the rest perfusion defects and more often are 
similar to stress-induced ischaemic perfusion defects (Figure 2). 
It should be noted that if the primary objective of the MIBG 
uptake assessment is not to diagnose the myocardial adrenergic 
innervation in a given population (compared to normal results), but 
the evaluation of any expected regional changes in the innervation 
in relation to the initial condition of a given patient or of any diffe-
rences in the regional innervation between well-defined groups of 
patients, then it is not critically necessary to have maps of normal 
uptake levels.
The quality of I-123-MIBG SPECT can be much lower than the 
quality of SPECT-based myocardial perfusion with technetium tra-
cers. As many as 16% of the I-123-MIBG SPECT examinations car-
ried out by our team [39] were non-diagnostic studies due to the 
very low uptake level within the myocardium and/or very high 
radioactivity in non-myocardial structures (liver, bowels, lungs), the 
images of which were not separated from myocardial images. Also 
Gill et al. [34] reported that the artefacts on the inferior left ventricu-
Figure 1. Planar anterior I-123-MIBG images obtained 4 hours after 
radiopharmaceutical injection in two patients with ischaemic heart 
failure. The counts per pixel within a circular ROI 1 (H) correspond 
to the global radioactivity accumulated in the heart. The counts per 
pixel within the square ROI 2 or ROI 3 (M, from the region with lower 
value) correspond to the non-specific radioactivity accumulated in the 
upper mediastinum. The heart-to-mediastinum ratio (H/M) is used as 
a measure of myocardial uptake of MIBG. A. Patient with high MIBG 
myocardial uptake (H/M4h = 2.54). B. Patient with lower MIBG uptake 
(H/M4h = 1.58) and a higher risk of major cardiac events
Figure 2. Comparison of the images of regional adrenergic innervation 
(at rest) and perfusion (at rest and under stress) of the left ventricular 
myocardium in SPECT studies. From each study, the summary uptake 
of the radiotracer (‘bull’s-eye’ map) is presented. I-123-MIBG uptake 
deficit evaluated at rest is much bigger than Tc-99m-MIBI uptake deficit 
at rest; rest image of the innervation is more corresponding to perfu-
sion image in stress conditions
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lar wall — due to the very high MIBG uptake in the liver or spleen 
in SPECT images registered within 3 hours after the administra-
tion of the tracer — were so frequent that the authors decided to 
discontinue the assessment of radiotracer distribution in this wall.
Necessity of standardisation of MIBG examinations
During their retrospective assessment of the studies relating to 
the myocardial adrenergic system, Agostini, Verberne and Jacobson 
determined large differences in the acquisition methods applied in 
Europe, which could affect the resulting parameters of the global 
MIBG uptake [27]. Their efforts to standardise the technical as-
pects of the procedure (and thus to increase the prospect that it 
is accepted as a clinical tool for patients with heart failure) [32, 33] 
resulted in a proposal for standardisation of I-123-MIBG imaging of 
the myocardial adrenergic system, announced by the Cardiovas-
cular Committee of the European Association of Nuclear Medicine 
and the European Council of Nuclear Cardiology [25]. It should 
contribute to reducing differences between results, including nu-
merical results, originating from various countries and centres [40].
Clinical applications of I-123-MIBG 
myocardial examinations 
Although first introduced as a cardiac diagnostic procedure 
in the early 1980s, I-123-MIBG myocardial scintigraphic me-
thods continue to be mostly applied in scientific research (Table 2). 
Their advantage over the existing diagnostic methods has not 
been sufficiently documented (lack of multi-centre randomised 
studies with large groups of patients), even though there are nu-
merous reports of the diagnostic and/or prognostic importance 
of this examination, especially in the case of heart failure. The 
testing results of MIBG-based examinations have been described 
for a variety of other heart diseases, including: primary arrhyth-
mias [41–43], myocardial ischaemia with infarction [14–17] or 
without [44–48], in the assessment of the development of the 
innervation system after heart transplant [11, 12, 49], in the as-
sessment of cardiotoxicity of anticancer chemotherapy [50–52]. 
There are also numerous reports showing that the I-123-MIBG 
imaging enables effective monitoring of the effects of conventional 
pharmacological therapies; images of MIBG uptake are improved 
after therapy with beta-blockers and often associated with reduced 
volume of the ventricles, better LVEF and reduced symptoms of 
heart failure; carvedilol has been most extensively researched 
in this respect (the recent randomised multi-centre double-blind 
placebo-controlled study was the French study described by 
Cohen-Solal in 2005 [53]); also other approved drugs which do not 
directly affect the myocardial adrenergic functions, such as ACE 
inhibitors, ARB blockers, spironolactone or amiodarone, have also 
been shown to improve MIBG uptake. MIBG-based myocardial 
examinations have also been applied in cardiomyopathies [13, 
54–58], myocarditis [59], and also in diabetic neuropathy [60–63, 
MIBG examinations will perhaps enable identifying high-risk 
patients — Nagamachi observed patients with type 2 diabetes, 
with no cardiological symptoms, for an average period of 7 years; 
H/M4h < 1.7 was an independent predictor of general mortality 
rate] and in neurological diseases (mainly in Parkinson’s disease). 
Furthermore I-123-MIBG was used in studies of the impact of trans-
myocardial laser revascularisation (TMLR) on live tissue, which 
showed that a damage of the myocardial adrenergic system can 
be responsible for the significant clinical improvement generally 
observed at an early stage after TMLR, however, in the light of 
reinnervation, it is not responsible for the improvement covering 
a period of several years [64–67]. 
Most recently MIBG imaging was applied for the assess-
ment of cardiac involvement and prediction of cardiac events in 
patients with Churg-Strauss syndrome (a rare variety of systemic 
vasculitis, often involving myocardial vessels) [68]. 
Below are discussed results of the studies relating to some 
selected clinical situations which have been described in a num-
ber of publications and new original works published over the 
past 2 years, which shows the continuous/increasing interest in 
I-123-MIBG myocardial examinations.
I-123-MIBG examinations in heart failure 
The clinical applications of I-123-MIBG in cardiology have been 
most extensively examined in patients with heart failure.
Heart failure (HF) is a condition with clinical symptoms of 
impaired heart performance — patients experience shortness of 
breath at rest or during exertion and/or fatigue, have symptoms of 
fluid retention, such as stasis in the pulmonary circulation or 
oedema around ankles, and the objective data suggest irregulari-
ties in the heart structure and functions at rest. The incidence of 
HF in Europe varies from 2 to 3%, but it increases rapidly around 
the age of 75 (10–20% in the age group of 70–80 years). Coronary 
artery disease is still the most frequent cause of myocardial disease 
and it is estimated to be a causative factor in about 70% of HF 
patients. The general prognosis in HF is poor; on average 50% of 
HF patients die within 4 years of the diagnosis [69]. 
The adrenergic nervous system plays one of the major roles in 
HF pathophysiology. The primary changes in HF are characte-
Table 2. Clinical applications of  I-123-MIBG myocardial 
examinations
Heart diseases
Heart failure 
Primary arrhythmias 
Coronary artery disease with infarction 
Myocardial ischaemia without infarction 
Assessment of the development of the innervation system after heart 
transplantation
Assessment of cardiotoxicity of anticancer chemotherapy
Monitoring of the effects of pharmacological therapies
Cardiomyopathies 
Myocarditis
Diabetic neuropathy
Churg-Strauss syndrome
Neurological diseases
Diseases with Lewy bodies: 
— Parkinson’s disease (PD) 
— Dementia with Lewy bodies (DLB)
Parkinson’s syndromes
Other types of dementia [mainly Alzheimer’s disease (AD)]
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rised by the increased activity of the adrenergic system (however, 
the precise cause of sympathetic activation in HF is not known). 
Initially, the increased sympathetic activation (greater conducti-
vity in the sympathetic nerves) is a compensating mechanism: 
increased noradrenaline (NE) secretion from the neuron terminal 
of the myocardial adrenergic system causes a greater amount of 
NE in the synaptic cleft and increases the myocardial contracti-
lity and heart rate. A small fraction of NE passes from the cleft 
to the blood circulation and thus increases the NE level in blood 
plasma, and the remaining NE is transported by NET back to the 
nerve terminal; increased NE secretion is usually associated with 
reduced NE reuptake to the nerve terminal due to the reduced 
sensitivity of the NET transporter. In patients with chronic HF the 
greater activity of the myocardial adrenergic system has adverse 
effects — increased NE concentration in the synaptic cleft de-
creases the sensitivity of post-synaptic adrenergic beta-1 recep-
tors on the cardiomyocyte membrane, reduces the activation 
conductivity and contributes to the impairment of heart functions. 
These changes in the activity of the myocardial adrenergic system 
are also relevant to the generation of ventricular arrhythmias and 
sudden cardiac death in HF patients.
As the reduced NE reuptake contributes to the low MIBG 
concentration in neurons (reduced H/M ratio) and the increased 
NE secretion causes greater MIBG washout (greater WR value), 
an assessment of the activity of the adrenergic system based on 
MIBG as well as H/M and WR imaging parameters is used for 
obtaining prognostic information in the case of HF patients.
The study of Merlet et al., published in 1992, was the first report 
showing that the myocardial MIBG uptake is a strong predictive 
factor for cardiac events in the case of patients with chronic HF 
[31]. Low H/M value was determined to be the best indepen-
dent predictor of the death rate, better than low EF value: after 
20 months the survival rate was 10% in the case of patients with 
H/M < 1.22, and 30% in the case of patients with EF < 20%. 
It has been shown in a number of single-centre studies that 
the myocardial MIBG uptake has a prognostic value for HF pa-
tients. Recently Agostini et al. have carried out a retrospective 
review and an important prospective quantitative re-analysis of 
the studies conducted over the past 10 years in 6 European 
centres with a view to verifying these observations based on the 
rigorous methodology of clinical studies [27]. Their study focused 
on the analysis of the H/M ratio after four hours (H/M4h), and more 
specifically, on account of considerable non-uniformity of the 
methods applied in each centre, after 2–7 hours from the admi-
nistration of a radiotracer — in HF patients, Class II–IV according 
to the NYHA classification. (Early scans were only available for 
28% of the patients, and SPECT results for 7% of the patients.) 
290 patients with EF < 50% (including 42% of the patients with 
ischaemic heart failure) were evaluated in the study. Major cardiac 
events (MCEs) defined as: cardiac death (infarction, HF progres-
sion, SCD), transplantation, potentially life-threatening arrhythmia, 
were observed over a period of 24 months. The images acquired 
during blind studies were subject to standardised assessment. In 
the MCE group, the average H/M4h ratio was 1.51 ± 0.3, and in 
the non-MCE group — 1.97 ± 0.54 (p < 0.0001). The optimised 
cut-off threshold for the H/M4h ratio was defined as 1.75; 2-year 
survival rate for non-MCE patients was 62% with lower values, and 
95% with values ≥ 1.75. Additionally, the non-MCE survival rate 
was 52% for the high-risk H/M4h value £ 1.45, and 98% for the 
low-risk H/M4h value ≥ 2.18. It was shown that the H/M4h parameter 
was the strongest independent predictor of the risk of MCE occur-
rence; the EF parameter ranked second, a weaker predictor. The 
assessment of interactions between EF and H/M4h values showed 
that the prognostic value of the H/M4h parameter was evident in 
the population of patients with intensified dysfunction of the left 
ventricle (EF £ 35%).
The application of the methodology used in clinical stu-
dies based on a retrospective analysis of MIBG uptake im-
ages confirmed the previously reported prognostic value of 
this method for HF patients, including a possibility of determining 
the numerical threshold indicating low risk of cardiac death, 
necessary transplantation or serious ventricular arrhythmias [27].
At the same time as Agostini et al. conducted their analysis, 
another study was published — a meta-analysis of 18 studies with 
a total of 1755 patients with heart failure (including 31% with is-
chaemic HF) — carried out by Verberne et al. [28]. The objective 
of the systematic review was to provide a critical assessment of the 
existing facts relating to the prognostic value of semi-quantitative 
myocardial I-123-MIBG uptake parameters (H/M15m, H/M4h, WR) 
for HF patients. The occurrence of cardiac death and cardiac 
events (cardiac death, stroke, transplantation, hospitalisation due 
to HF progression) was assessed. It was shown that patients with 
reduced H/M4h ratio or greater WR value have a considerably 
worse prognosis.
Recently there were published the results of the first large (961 
patients with EF £ 35% and assigned to Class II-III according to the 
NYHA classification) multi-centre international prospective study 
conducted by Jacobson et al. (ADMIRE-HF Study [26]) which 
included 96 centres from North America and Europe. The study 
focused on the analysis of the H/M4h parameter. Control observa-
tions covered a period of 2 years. The endpoint was determined 
as the occurrence of a cardiac event defined as a progression of 
NYHA class or occurrence of potentially life-threatening arrhyth-
mia or cardiac death. It was compared to H/M4h values in relation 
to the adopted lower limit (H/M4h = 1.6) or taking the H/M4h ratio 
as a continuous variable. The study confirmed that symptomatic 
patients with heart failure have worse prognosis with reduced myo-
cardial I-123-MIBG uptake. The percentage of cardiac events within 
the observation period of 2 years was 15% at H/M4h ≥ 1.6 and 
was significantly greater at H/M4h < 1.6 (37%). The ADMIRE-HF 
study confirmed the independent prognostic value of I-123-MIBG 
scintigraphy for the assessment of patients with heart failure.
The main cause of death in the case of HF patients is cardiac 
death due to ventricular disorders of heart rate. In the case of some 
patients the final arrhythmia is a natural result of the end-stage 
irreversible heart pump dysfunction; while in the case of some 
patients functioning quite well, sudden cardiac death (SCD) oc-
curs. It was suggested in numerous studies that the disorders of 
MIBG uptake can be used as predictors of the higher risk of ser-
ious ventricular arrhythmias and SCD [43,70–73]. On the other 
hand, a high level of myocardial MIBG uptake, measured by the 
H/M ratio, has a high value as a negative predictor, especially for 
potentially life-threatening arrhythmias. Thus, the results of extended 
MIBG studies can be used in the future for optimising therapy for 
HF patients, in particular when considering very expensive thera-
pies involving specialist devices, such as implantable cardioverter 
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defibrillator (ICD), cardiac resynchronisation therapy (CRT), left 
ventricular assist device (LVAD) [73, 74].
I-123-MIBG studies can also be used for monitoring the ef-
ficacy of these therapies. The recently published study of Drakos et 
al. [75], in which patients at the end-stage of HF and provided 
with LVAD were described, showed that the clinical, functional and 
haemodynamic improvement observed after 3 months was as-
sociated with better MIBG uptake and washout parameters in 
scintigraphic imaging. Another recently published study showed 
that the reduced H/M ratio was associated with weak response to 
the applied cardiac resynchronisation therapy [76].
I-123-MIBG myocardial imaging in neurological 
pathological conditions
Since 1994 there have been published papers describing the 
application of MIBG myocardial scintigraphy as a diagnostic and 
potentially prognostic tool in neurological pathological conditions, 
mainly Parkinson’s disease. 
A distinctive objective of neuroimaging techniques is to enable 
differentiating between neurodegenerative diseases, in particular 
diseases with Lewy bodies — including Parkinson’s disease (PD) 
or dementia with Lewy bodies (DLB) — and Parkinson’s syn-
dromes or other types of dementia [including Alzheimer’s disease 
(AD)] on account of the significant differences in their treatment. 
The accuracy of clinical diagnostic criteria for these diseases is li-
mited; the similarity between specific clinical symptoms can delay 
diagnosis and application of treatment. 
In 1994 Hakusui et al. [77] described a total lack of myocar-
dial MIBG accumulation in patients with Parkinson’s disease. 
Five years later Satoh et al. [78] demonstrated not so much 
non-existence of uptake as substantially reduced uptake, based 
on the H/M ratio, in patients with Parkinson’s disease compared to 
healthy subjects – which was confirmed in the subsequent studies. 
Recently Muxi et al. have shown that the significantly reduced 
H/M4h ratio is a scintigraphic parameter which best differentia-
tes between PD patients and healthy people and that the optimised 
threshold value of 1.43 detects PD with sensitivity at 93% and 
specificity at 100% [40]. 
Sawada et al. have assessed the diagnostic accuracy of 
I-123-MIBG scintigrams in detecting Parkinson’s disease in 
a large group (400 patients) suspected of this disease [79]. In 
267 patients the disease was diagnosed based on diagnostic 
criteria and confirmed based on magnetic resonance results. The 
myocardial MIBG accumulation was significantly reduced in PD 
patients (H/M20m was 1.66 vs. 2.39 in non-PD patients, and the 
H/M4h ratio was 1.44 vs. 2.42). With an optimised cut-off threshold 
at 1.68 for H/M4h, the sensitivity of PD detection was 84% and 
specificity 90%. However, in a subgroup of patients diagnosed 
with the disease not more than 3 years earlier, the sensitivity of 
PD detection was 73% and specificity 88% with an optimised 
cut-off threshold at 1.8 for H/M4h. The authors determined that the 
diagnostic accuracy of MIBG myocardial scintigraphy is limited 
in the case of patients with early-stage PD due to the insufficient 
sensitivity.
Similarly, the study of Ishibashi et al., in which PD was diag-
nosed based on clinical criteria and PET dopamine tests, and 
compared to Parkinson’s syndromes (non-PD), showed that 
MIBG scintigraphy has a limited diagnostic value for patients with 
early-stage PD. In a general group of PD patients, with an optimised 
cut-off threshold for H/M4h at 1.60, the sensitivity was determined 
at 71% and specificity at 93% for the disease detection, but in 
a subgroup of patients with early-stage disease, the sensitivity 
was only 54% [80].
The reduced MIBG uptake and the corresponding degenera-
tion of the myocardial sympathetic innervation was observed in 
early stages of DLB and PD by Suzuki et al., and the functions of the 
adrenergic system, measured with the H/M ratio, was significantly 
reduced in DLB patients compared to PD patients [81].
In the differentiation between DLB and Alzheimer’s disease 
it was shown that the H/M ratio is significantly lower in DLB 
patients [82, 83]. In the studies of Yoshita et al. the optimised 
threshold value at 1.68 for H/M4h enabled 100% sensitivity and 
specificity of the differentiation process; it was also shown that 
the WR value at 23.6% enables differentiating between DLB (with 
greater washout rate) and Alzheimer’s disease with sensitivity at 
84% and specificity at 83% [83]. 
Estorch et al. investigated the possibility of early MIBG-based 
diagnostic differentiation between DLB and other neurodege-
nerative diseases characterised by cognitive disorders [84]. The 
results of MIBG-based examinations at an early stage of the 
disease were verified based on the final clinical diagnosis made 
4 years later, after the disease developed. The H/M ratio was sig-
nificantly reduced in patients diagnosed with DLB in relation 
to patients with other neurodegenerative diseases. The H/M4h 
ratio at 1.36 enabled differentiating between DLB and other di-
seases with sensitivity at 94% and specificity at 96%, while the 
WR value was significantly higher in DLB patients only compared 
to patients with Alzheimer’s disease (34% vs. 22%). 
Conclusions
Although first introduced as a cardiac diagnostic procedure 30 
years ago, I-123-MIBG myocardial scintigraphic methods continue 
to be mostly applied in scientific research. Their advantage over the 
existing diagnostic methods has not been sufficiently documented 
(lack of multi-centre randomised studies with large groups of pa-
tients), even though there are numerous reports of the diagnostic 
and/or prognostic importance of this examination, especially in the 
case of heart failure. The testing results of MIBG-based examina-
tions have been described for a variety of heart diseases, includ-
ing: primary arrhythmia, myocardial ischaemia, cardiomyopathies, 
myocarditis, diabetic neuropathy, in relation to the assessment of 
the development of the innervation system after heart transplant, 
assessment of cardiotoxicity of anticancer chemotherapy, monito-
ring of the therapy effects, and in neurological diseases (mainly 
Parkinson’s disease). 
The paper discusses in more detail the testing results in 
some clinical situations which have been described in a number 
of publications and new original papers over the past 2 years, 
demonstrating the continuous/growing interest in I-123-MIBG 
myocardial examinations. 
The results of two extensive retrospective works and a major 
prospective, multi-centre international ADMIRE-HF study, pub-
lished in the recent years, confirmed that I-123-MIBG scintigraphy 
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has a high independent prognostic value for the assessment of 
patients suffering from heart failure: patients with the lowest MIBG 
uptake are patients with the worst prognosis. Improper myocardial 
I-123-MIBG uptake can be indicative of the increased risk of ven-
tricular arrhythmia and SCD in patients with heart failure.
I-123-MIBG myocardial scintigraphy seems also to have 
a considerable potential for detection and differentiation of neuro-
degenerative diseases. In the case of diseases with Lewy bodies, 
such as Parkinson’s disease and dementia with Lewy bodies, 
the functions of the adrenergic system are to a significant extent 
worse compared to the healthy population and patients with Par-
kinson’s syndromes or other types of dementia. Furthermore, the 
functions of the cardiac adrenergic system are significantly worse 
in patients suffering from dementia with Lewy bodies compared 
to patients with Parkinson’s disease, Alzheimer’s disease or other 
neurodegenerative diseases characterised by cognitive disorders. 
However, the sensitivity of MIBG-based myocardial scintigraphy in 
detecting early stage of Parkinson’s disease seems to be limited.
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